Lv42
596 积分 2021-11-22 加入
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases
3小时前
待确认
Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta-analysis
14小时前
待确认
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
4天前
已完结
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
4天前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial
4天前
已完结
Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes
6天前
已完结
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
6天前
已完结
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
11天前
已完结
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
16天前
已完结
Residual cardiovascular risk is tracked by apolipoprotein B in coronary patients with elevated serum triglyceride levels: the ESC EORP EUROASPIRE IV survey
16天前
已完结
皖公网安备34019202002308
